Tricia R. Cottrell
YOU?
Author Swipe
View article: 97 Statistical and systematic uncertainties affect biomarker reliability: a case study in multiplex immunofluorescence
97 Statistical and systematic uncertainties affect biomarker reliability: a case study in multiplex immunofluorescence Open
View article: 427 Mapping the expression of therapeutically targetable molecules in the tumor microenvironment of malignant pleural mesothelioma
427 Mapping the expression of therapeutically targetable molecules in the tumor microenvironment of malignant pleural mesothelioma Open
View article: 167 Assessment of pathologic complete response following neoadjuvant therapy in patients with resectable lung cancer is equivalent across scoring systems
167 Assessment of pathologic complete response following neoadjuvant therapy in patients with resectable lung cancer is equivalent across scoring systems Open
View article: 1230 Enhancing tissue microarray design for immune profiling: tissue microarray vs whole-slide quantification of CD8 in non-small cell lung carcinoma
1230 Enhancing tissue microarray design for immune profiling: tissue microarray vs whole-slide quantification of CD8 in non-small cell lung carcinoma Open
View article: 64 A novel application of selective exo-enzymatic glycan labeling to co-quantify cell-surface glycans and protein-based biomarkers of the tumour immune microenvironment
64 A novel application of selective exo-enzymatic glycan labeling to co-quantify cell-surface glycans and protein-based biomarkers of the tumour immune microenvironment Open
View article: Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses
Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses Open
Immune checkpoint blockade (ICB) is standard of care in advanced diffuse pleural mesothelioma (DPM), but its role in the perioperative management of DPM is unclear. In tandem, circulating tumor DNA (ctDNA) ultra-sensitive residual disease …
View article: Novel Predictive Spatial Biomarker in Non-Small Cell Lung Carcinoma: The Diversity of Niches Unlocking Treatment Sensitivity (DONUTS)
Novel Predictive Spatial Biomarker in Non-Small Cell Lung Carcinoma: The Diversity of Niches Unlocking Treatment Sensitivity (DONUTS) Open
SUMMARY Probabilistic spatial modelling techniques developed on large-scale tumor-immune Atlases (∼35M individually mapped cells; 50,000 high power fields) were used to characterize predictive features of treatment-responsive lung cancer. …
View article: Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols Open
Immunotherapy of cancer is now an essential pillar of treatment for patients with many individual tumor types. Novel immune targets and technical advances are driving a rapid exploration of new treatment strategies incorporating immune age…
View article: Figure S4 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Figure S4 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade Open
Figure S4
View article: Figure S2 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Figure S2 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade Open
Figure S2
View article: Figure S5 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Figure S5 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade Open
Figure S5
View article: Figure S6 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Figure S6 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade Open
Figure S6
View article: Figure S1 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Figure S1 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade Open
Figure S1
View article: Figure S3 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Figure S3 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade Open
Figure S3
View article: Supplementary Tables 1 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Supplementary Tables 1 from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade Open
Tables S1-S4
View article: Data from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Data from Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i>Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade Open
Purpose:Co-mutations of the Kirsten rat sarcoma virus (KRAS) and serine/threonine kinase 11 (STK11) genes in advanced non–small cell lung cancer (NSCLC) are associated with immune checkpoint blockade (ICB…
View article: Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial
Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial Open
View article: Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i> Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade
Divergent Clinical and Immunologic Outcomes Based on <i>STK11</i> Co-mutation Status in Resectable <i>KRAS-</i> Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade Open
Purpose: Co-mutations of the Kirsten rat sarcoma virus (KRAS) and serine/threonine kinase 11 (STK11) genes in advanced non–small cell lung cancer (NSCLC) are associated with immune checkpoint blockade (ICB) resistance. Although neoadjuvant…
View article: SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials
SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials Open
View article: A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Cancer
A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Cancer Open
View article: 222-N Analysis of pathologic features and efficacy outcomes with neoadjuvant nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer in CheckMate 816
222-N Analysis of pathologic features and efficacy outcomes with neoadjuvant nivolumab plus platinum-doublet chemotherapy for resectable non-small cell lung cancer in CheckMate 816 Open
Background Pathologic response assessment after neoadjuvant treatment is the potential analog to radiographic response for advanced disease, with regard to study design, clinical care, and accelerated regulatory approvals. A standardized s…
View article: 121 Quantifying statistical and systematic uncertainties in predicting clinical outcomes using multiplex immunofluorescence
121 Quantifying statistical and systematic uncertainties in predicting clinical outcomes using multiplex immunofluorescence Open
Background Statistical analysis of multiplex immunofluorescence images can be used to predict patient outcomes. Recent advances have enabled complex analyses of marker expressions across every cell on a slide, as well as their spatial corr…
View article: 1511 Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant IO trials (PATHdata): Interim analysis of a multi-institutional reproducibility study
1511 Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant IO trials (PATHdata): Interim analysis of a multi-institutional reproducibility study Open
Background Immunotherapeutic agents are now being investigated for treating earlier-stage cancers. Radiographic assessment by RECIST, widely used to assess treatment response in clinical trials for advanced cancers, has limitations in the …
View article: Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Association between pathologic response and survival after neoadjuvant therapy in lung cancer Open
Neoadjuvant immunotherapy plus chemotherapy improves event-free survival (EFS) and pathologic complete response (0% residual viable tumor (RVT) in primary tumor (PT) and lymph nodes (LNs)), and is approved for treatment of resectable lung …
View article: Supplementary Figures from Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer
Supplementary Figures from Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer Open
Figures S1-S8
View article: Supplementary Methods from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Supplementary Methods from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy Open
Supplementary methods
View article: Supplementary Figures S1-S14 from Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Supplementary Figures S1-S14 from Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer Open
Supplementary Figure S1. ctDNA clonal dynamics during anti-PD1 for patients with a clinical response. Supplementary Figure S2. ctDNA clonal dynamics during anti-PD1 for patients with molecular primary resistance. Supplementary Figure S3. c…
View article: Table S2 from Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer
Table S2 from Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer Open
Correlative assays performed on each sample
View article: Supplementary Table S2 from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy
Supplementary Table S2 from Transcriptional Mechanisms of Resistance to Anti–PD-1 Therapy Open
Functionally annotated gene categories from DAVID analysis of Illumina probes differentially expressed between regressing vs. progressing melanoma metastases
View article: Data from Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer
Data from Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer Open
Purpose:Neoadjuvant PD-1 blockade is a promising treatment for resectable non–small cell lung cancer (NSCLC), yet immunologic mechanisms contributing to tumor regression and biomarkers of response are unknown. Using paired tumor/blood samp…